Witiak D T, Poochikian G K, Feller D R, Kenfield N A, Newman H A
J Med Chem. 1975 Oct;18(10):992-6. doi: 10.1021/jm00244a008.
The synthesis and antilipidemic activity of 9-chloro-2,3-dihydro-5H-1,4-dioxepino[6,5-b]benzofuran (3), a novel enol lactone which is considerably more resistant to serum esterase hydrolysis than clofibrate (1), are discussed. Whereas both 3 and 1 reduced hypercholesterolemic and hypertriglyceridemic serum levels in the Triton WR-1339 induced hyperlipidemic Sprague-Dawley rat to normal, the hydrolysis product of 3, namely 5-chloro-3(2'-hydroxyethoxy)-2-benzofurancarboxylic acid (4), was found to be inactive. Further, 3 is comparable to the hydrolysis product of 1 when both were assessed for their ability to block norepinephrine (NE) induced lipolysis in vitro. 4 is inactive at comparable concentrations (5 times 10(-4)-10(-3) M). The antilipidemic action of 3 and 1 may, in part, be due to their ability to block NE-induced lipolysis.
讨论了新型烯醇内酯9-氯-2,3-二氢-5H-1,4-二氧杂环庚并[6,5-b]苯并呋喃(3)的合成及其抗血脂活性,该化合物比氯贝丁酯(1)对血清酯酶水解的耐受性强得多。虽然3和1均可使Triton WR-1339诱导的高脂血症斯普拉格-道利大鼠的高胆固醇血症和高甘油三酯血症血清水平恢复正常,但3的水解产物,即5-氯-3(2'-羟基乙氧基)-2-苯并呋喃羧酸(4),被发现无活性。此外,当评估3和1的水解产物体外阻断去甲肾上腺素(NE)诱导的脂解作用的能力时,二者相当。4在相当浓度(5×10(-4)-10(-3) M)下无活性。3和1的抗血脂作用可能部分归因于它们阻断NE诱导的脂解作用的能力。